Merck Looks To “Exploit” Switches With Exit From J&J Joint Venture
Merck gains flexibility to pursue Rx-to-OTC switches, such as allergy drug Clarinex and cholesterol treatment Zetia by exiting its OTC joint venture with Johnson & Johnson.
Merck gains flexibility to pursue Rx-to-OTC switches, such as allergy drug Clarinex and cholesterol treatment Zetia by exiting its OTC joint venture with Johnson & Johnson.